TCR2 Therapeutics Inc. (NASDAQ: TCRR) stock fell -0.95% on Friday to $3.12 against a previous-day closing price of $3.15. With 0.15 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.48 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.1700 whereas the lowest price it dropped to was $3.0200. The 52-week range on TCRR shows that it touched its highest point at $19.03 and its lowest point at $2.07 during that stretch. It currently has a 1-year price target of $13.89. Beta for the stock currently stands at 1.83.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TCRR was down-trending over the past week, with a drop of -6.02%, but this was up by 9.09% over a month. Three-month performance surged to 29.46% while six-month performance fell -12.36%. The stock lost -75.41% in the past year, while it has lost -33.05% so far this year. A look at the trailing 12-month EPS for TCRR yields -2.80 with Next year EPS estimates of -2.36. For the next quarter, that number is -0.79. This implies an EPS growth rate of -9.70% for this year and 11.90% for next year. EPS is expected to decline by 0.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -41.60%.
Float and Shares Shorts:
At present, 38.51 million TCRR shares are outstanding with a float of 36.92 million shares on hand for trading. On Apr 28, 2022, short shares totaled 2.02 million, which was 5.25% higher than short shares on Mar 30, 2022. In addition to Dr. Garry E. Menzel M.B.A., Ph.D. as the firm’s Pres, CEO & Director, Dr. Patrick A. Baeuerle Ph.D. serves as its Founder & Member of the Advisory Board.
Through their ownership of 88.87% of TCRR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.51% of TCRR, in contrast to 40.64% held by mutual funds. Shares owned by individuals account for 11.63%. As the largest shareholder in TCRR with 7.78% of the stake, Tang Capital Management LLC holds 3,000,000 shares worth 3,000,000. A second-largest stockholder of TCRR, BlackRock Fund Advisors, holds 2,250,549 shares, controlling over 5.84% of the firm’s shares. Renaissance Technologies LLC is the third largest shareholder in TCRR, holding 1,442,600 shares or 3.74% stake. With a 2.25% stake in TCRR, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 868,012 shares are owned by the mutual fund manager. The JPMorgan Funds – Thematics – Gene, which owns about 1.90% of TCRR stock, is the second-largest Mutual Fund holder. It holds 733,891 shares valued at 2.13 million. Vanguard Extended Market Index Fu holds 1.14% of the stake in TCRR, owning 438,705 shares worth 1.27 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TCRR since 9 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TCRR analysts setting a high price target of $29.00 and a low target of $2.00, the average target price over the next 12 months is $13.89. Based on these targets, TCRR could surge 829.49% to reach the target high and fall by -35.9% to reach the target low. Reaching the average price target will result in a growth of 345.19% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. TCRR will report FY 2022 earnings on 04/03/2023. Analysts have provided yearly estimates in a range of -$2.33 being high and -$3.52 being low. For TCRR, this leads to a yearly average estimate of -$2.98. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. TCR2 Therapeutics Inc. surprised analysts by -$0.03 when it reported -$0.76 EPS against a consensus estimate of -$0.73. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.72 and the low estimate is -$0.88. The average estimate for the next quarter is thus -$0.78.
Summary of Insider Activity:
Insiders traded TCRR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 222,626 while 0 shares were sold.